Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S.

Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.

Aurobindo Pharma to acquire US-based Lannett for $250M, gaining a strategic local manufacturing base to offset tariffs and ...

Aurobindo Pharma USA acquires Lannett Company LLC for $250 million, expanding U.S. manufacturing capabilities and product ...

Lannett Company, Inc. (Nasdaq: LCI) is a pure play generic drug manufacturer based in Philadelphia. It has a diversified portfolio of generic drugs including over 100 marketed products and 250 SKUs.

Lannett is selling its liquid drug manufacturing facility in Carmel, N.Y., as well as equipment located at the facility, certain ANDAs and other assets to a private company for $10.5 million in ...

Lannett cannot possibly sustain their Levo supply agreement at current terms. This distribution deal, which expires in 2019, will either fall due to price fixing, or be dramatically repriced.

Lannett is now operating as a privately held company under the ownership of its pre-petition lenders. Trevose generic drug company to restructure debt, file for bankruptcy Trevose generic drug ...

Lannett CEO Arthur Bedrosian has slammed Shkreli. Yet his company boosted the cost of fluphenazine, which treats certain kinds of schizophrenia, to a net price of $195.53 from $11.17 between April ...

Shares in Lannett Co. plunged 55% Monday after the generic-pharmaceuticals maker said a distribution pact with a key supplier won’t be renewed next year and that it would expand restructuring ...

Shares of Lannett plunged by 12.9% on Monday after the Food & Drug Administration said it planned to withdraw approval of its generic treatment for attention deficit hyperactivity disorder. The ...